Towards detecting the HER-2 receptor and metabolic changes induced by HER-2 targeted therapies using medical imaging

Timothy A D Smith

Research output: Contribution to journalLiterature review

16 Citations (Scopus)
4 Downloads (Pure)

Abstract

HER-2/neu (human epidermal growth factor receptor) is involved in cell survival, proliferation, angiogenesis and invasiveness and is overexpressed in about 25% of breast cancers. Overexpression of HER-2 is associated with response to the anti-HER-2 antibody Trastuzumab (Herceptin). However HER-2 expression can be heterogeneous within the primary tumour and exhibit discordance in expression between a primary tumour and its metastasis bringing into question the practise of HER-2 screening for trastuzumab candidate patients using material obtained only from the primary tumour. Medical imaging modalities using HER-2 targeted tracers (or contrast agents) facilitate a global approach to the determination of HER-2 expression across all detectable tumour lesions carried by the patient and could provide a more reliable indication of the patient’s likely response to trastuzumab treatment. Here is reviewed the development and preclinical (and occasional clinical) assessment of HER-2 targeted tracers along with studies detailing the use of established imaging tracers such as 11C-choline in the determination of response to tratsuzumab for a range of medical imaging modalities including PET (positron emission tomography), SPECT (single photon emission tomography), MRI and optical imaging.

Original languageEnglish
Pages (from-to)638-644
Number of pages7
JournalBritish Journal of Radiology
Volume83
Issue number992
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Diagnostic Imaging
Neoplasms
Optical Imaging
Therapeutics
Choline
Single-Photon Emission-Computed Tomography
Photons
Positron-Emission Tomography
Contrast Media
Cell Survival
Tomography
Cell Proliferation
Breast Neoplasms
Neoplasm Metastasis
Trastuzumab
Antibodies

Cite this

Towards detecting the HER-2 receptor and metabolic changes induced by HER-2 targeted therapies using medical imaging. / Smith, Timothy A D.

In: British Journal of Radiology, Vol. 83, No. 992, 08.2010, p. 638-644.

Research output: Contribution to journalLiterature review

@article{70694d378e5b468b91d2c8c16c79ef28,
title = "Towards detecting the HER-2 receptor and metabolic changes induced by HER-2 targeted therapies using medical imaging",
abstract = "HER-2/neu (human epidermal growth factor receptor) is involved in cell survival, proliferation, angiogenesis and invasiveness and is overexpressed in about 25{\%} of breast cancers. Overexpression of HER-2 is associated with response to the anti-HER-2 antibody Trastuzumab (Herceptin). However HER-2 expression can be heterogeneous within the primary tumour and exhibit discordance in expression between a primary tumour and its metastasis bringing into question the practise of HER-2 screening for trastuzumab candidate patients using material obtained only from the primary tumour. Medical imaging modalities using HER-2 targeted tracers (or contrast agents) facilitate a global approach to the determination of HER-2 expression across all detectable tumour lesions carried by the patient and could provide a more reliable indication of the patient’s likely response to trastuzumab treatment. Here is reviewed the development and preclinical (and occasional clinical) assessment of HER-2 targeted tracers along with studies detailing the use of established imaging tracers such as 11C-choline in the determination of response to tratsuzumab for a range of medical imaging modalities including PET (positron emission tomography), SPECT (single photon emission tomography), MRI and optical imaging.",
author = "Smith, {Timothy A D}",
year = "2010",
month = "8",
doi = "10.1259/bjr/31053812",
language = "English",
volume = "83",
pages = "638--644",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "992",

}

TY - JOUR

T1 - Towards detecting the HER-2 receptor and metabolic changes induced by HER-2 targeted therapies using medical imaging

AU - Smith, Timothy A D

PY - 2010/8

Y1 - 2010/8

N2 - HER-2/neu (human epidermal growth factor receptor) is involved in cell survival, proliferation, angiogenesis and invasiveness and is overexpressed in about 25% of breast cancers. Overexpression of HER-2 is associated with response to the anti-HER-2 antibody Trastuzumab (Herceptin). However HER-2 expression can be heterogeneous within the primary tumour and exhibit discordance in expression between a primary tumour and its metastasis bringing into question the practise of HER-2 screening for trastuzumab candidate patients using material obtained only from the primary tumour. Medical imaging modalities using HER-2 targeted tracers (or contrast agents) facilitate a global approach to the determination of HER-2 expression across all detectable tumour lesions carried by the patient and could provide a more reliable indication of the patient’s likely response to trastuzumab treatment. Here is reviewed the development and preclinical (and occasional clinical) assessment of HER-2 targeted tracers along with studies detailing the use of established imaging tracers such as 11C-choline in the determination of response to tratsuzumab for a range of medical imaging modalities including PET (positron emission tomography), SPECT (single photon emission tomography), MRI and optical imaging.

AB - HER-2/neu (human epidermal growth factor receptor) is involved in cell survival, proliferation, angiogenesis and invasiveness and is overexpressed in about 25% of breast cancers. Overexpression of HER-2 is associated with response to the anti-HER-2 antibody Trastuzumab (Herceptin). However HER-2 expression can be heterogeneous within the primary tumour and exhibit discordance in expression between a primary tumour and its metastasis bringing into question the practise of HER-2 screening for trastuzumab candidate patients using material obtained only from the primary tumour. Medical imaging modalities using HER-2 targeted tracers (or contrast agents) facilitate a global approach to the determination of HER-2 expression across all detectable tumour lesions carried by the patient and could provide a more reliable indication of the patient’s likely response to trastuzumab treatment. Here is reviewed the development and preclinical (and occasional clinical) assessment of HER-2 targeted tracers along with studies detailing the use of established imaging tracers such as 11C-choline in the determination of response to tratsuzumab for a range of medical imaging modalities including PET (positron emission tomography), SPECT (single photon emission tomography), MRI and optical imaging.

U2 - 10.1259/bjr/31053812

DO - 10.1259/bjr/31053812

M3 - Literature review

VL - 83

SP - 638

EP - 644

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 992

ER -